Therapeutic Response

BCR::ABL1 status confers therapeutic sensitivity to Daunorubicin in combination with Dexamethasone, Imatinib, Methotrexate, and Vincristine in patients with Acute Lymphoblastic Leukemia.

View API

Statements

Source and description

View API